Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve the B-cells or T-cells of the immune system and often present as tumors in the lymph nodes. These high-grade cancers will move into the advanced stages much faster than indolent, low-grade tumors.
The Zevalin radioimmunotherapy regimen is now approved for treatment of certain follicular lymphomas
Patients who are looking for more advanced treatment or who have lymphoma that does not respond to standard treatment may want to consider a clinical study. Click here to find clinical trials in your area.
SupportGroups.com is for individuals, friends and families who are looking to connect during life's challenging times. Share personal experiences, evaluate information and get support during times of need, illness, treatment or recovery.
The information provided on the Lymphoma Information Network is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational and educational purposes. The publication of this information does not constitute the practice of medicine, and this information does not replace the advice of your physician or other health care provider. Neither the owners or employees of LymphomaInfo.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
Zevalin is the first radioummunotherapy treatment to be FDA-approved as a first-line therapy for lymphoma. Read more...
More Information
SupportGroups.com is for individuals, friends and families who are looking to connect during life's challenging times. Share personal experiences, evaluate information and get support during times of need, illness, treatment or recovery.
Since the early 1970s, incidence rates for non-Hodgkin’s lymphoma have nearly doubled. Improved diagnosis has contributed greatly to the increase as doctors better understand cancer of lymphocytes and can distinguish it from other diseases.